drugset / Trial / NCT02434276

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

NCT02434276

RandomizedParallel-groupDouble-blindPrevention

Summary

This is a multi-center, randomized, double-blind, active comparator controlled study in which up to 450 healthy adults age 18-64 years will be administered either one of two dose levels of VAX2012Q or a licensed quadrivalent influenza vaccine. The subjects will be randomized at a 1:1:1 ratio.

Timeline

Start
2015-05
Primary completion
2015-08
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Influenza Virus Vaccine Vaccine
Subject VAX2012Q Vaccine 8 ug
Subject VAX2012Q Vaccine 12 ug

Indications